The immune system, amyloid-β peptide, and Alzheimer's disease

被引：53

作者：

Weksler, ME

Gouras, G

Relkin, NR

Szabo, P

机构：

[1] Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA

[2] Cornell Univ, Weill Med Coll, Dept Neurol, New York, NY 10021 USA

来源：

IMMUNOLOGICAL REVIEWS | 2005年 / 205卷

关键词：

D O I：

10.1111/j.0105-2896.2005.00264.x

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In this review, the case is made that amyloid-beta peptide in the brain of patients with Alzheimer's disease is a primary cause of the disease and that immunotherapy directed against this peptide has the potential to halt and/or reverse disease progression. This supposition is supported by the capacity of anti-beta-amyloid peptide antibodies to prevent or reverse the disease in mouse models of Alzheimer's disease. Furthermore, preliminary results obtained in a small number of patients with Alzheimer's disease are consistent with the observations made in the mouse model of this disease. We review the relationship between the immune system, amyloid-beta peptide, and Alzheimer's disease and the progress made in applying immunotherapy to patients with Alzheimer's disease.

引用

收藏

页码：244 / 256

页数：13

相关论文

共 79 条

[21] Aging renders the brain vulnerable to amyloid β-protein neurotoxicity [J].

Geula, C ;

Wu, CK ;

Saroff, D ;

Lorenzo, A ;

Yuan, ML ;

Yankner, BA .

NATURE MEDICINE, 1998, 4 (07) :827-831

[22] Intracellular mechanisms of amyloid accumulation and pathogenesis in Alzheimer's disease [J].

Glabe, C .

JOURNAL OF MOLECULAR NEUROSCIENCE, 2001, 17 (02) :137-145

[23]

GLENNER GG, 1994, BIOCHEM BIOPH RES CO, V122, P1131

[24] Intraneuronal Aβ42 accumulation in human brain [J].

Gouras, GK ;

Tsai, J ;

Naslund, J ;

Vincent, B ;

Edgar, M ;

Checler, F ;

Greenfield, JP ;

Haroutunian, V ;

Buxbaum, JD ;

Xu, HX ;

Greengard, P ;

Relkin, NR .

AMERICAN JOURNAL OF PATHOLOGY, 2000, 156 (01) :15-20

[25] AUTOANTIBODIES AND THE PHYSIOLOGICAL-ROLE OF IMMUNOGLOBULINS [J].

GRABAR, P .

IMMUNOLOGY TODAY, 1983, 4 (12) :337-340

[26] Toward Alzheimer therapies based on genetic knowledge [J].

Hardy, J .

ANNUAL REVIEW OF MEDICINE, 2004, 55 :15-25

[27] Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease [J].

Hock, C ;

Konietzko, U ;

Streffer, JR ;

Tracy, J ;

Signorell, A ;

Müller-Tillmanns, B ;

Lemke, U ;

Henke, K ;

Moritz, E ;

Garcia, E ;

Wollmer, MA ;

Umbricht, D ;

de Quervain, DJF ;

Hofmann, M ;

Maddalena, A ;

Papassotiropoulos, A ;

Nitsch, RM .

NEURON, 2003, 38 (04) :547-554

[28] Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease [J].

Hock, C ;

Konietzko, U ;

Papassotiropoulos, A ;

Wollmer, A ;

Streffer, J ;

von Rotz, RC ;

Davey, G ;

Moritz, E ;

Nitsch, RM .

NATURE MEDICINE, 2002, 8 (11) :1270-1275

[29] Plaque-independent disruption of neural circuits in Alzheimer's disease mouse models [J].

Hsia, AY ;

Masliah, E ;

McConlogue, L ;

Yu, GQ ;

Tatsuno, G ;

Hu, K ;

Kholodenko, D ;

Malenka, RC ;

Nicoll, RA ;

Mucke, L .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (06) :3228-3233

[30] Correlative memory deficits, A beta elevation, and amyloid plaques in transgenic mice [J].

Hsiao, K ;

Chapman, P ;

Nilsen, S ;

Eckman, C ;

Harigaya, Y ;

Younkin, S ;

Yang, FS ;

Cole, G .

SCIENCE, 1996, 274 (5284) :99-102

← 1 2 3 4 5 6 7 8 →